841 related articles for article (PubMed ID: 11496242)
1. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
2. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma.
Martin PL; Fisher D; Glass W; O'Neil K; Das A; Martin EC; Li L
Int J Toxicol; 2008; 27(5):351-8. PubMed ID: 19037805
[TBL] [Abstract][Full Text] [Related]
3. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
4. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
[TBL] [Abstract][Full Text] [Related]
5. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys.
Bree A; Schlerman FJ; Wadanoli M; Tchistiakova L; Marquette K; Tan XY; Jacobson BA; Widom A; Cook TA; Wood N; Vunnum S; Krykbaev R; Xu X; Donaldson DD; Goldman SJ; Sypek J; Kasaian MT
J Allergy Clin Immunol; 2007 May; 119(5):1251-7. PubMed ID: 17379289
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
9. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.
Busse WW; Katial R; Gossage D; Sari S; Wang B; Kolbeck R; Coyle AJ; Koike M; Spitalny GL; Kiener PA; Geba GP; Molfino NA
J Allergy Clin Immunol; 2010 Jun; 125(6):1237-1244.e2. PubMed ID: 20513521
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
11. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.
Kolbeck R; Kozhich A; Koike M; Peng L; Andersson CK; Damschroder MM; Reed JL; Woods R; Dall'acqua WW; Stephens GL; Erjefalt JS; Bjermer L; Humbles AA; Gossage D; Wu H; Kiener PA; Spitalny GL; Mackay CR; Molfino NA; Coyle AJ
J Allergy Clin Immunol; 2010 Jun; 125(6):1344-1353.e2. PubMed ID: 20513525
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.
Kim S; Marigowda G; Oren E; Israel E; Wechsler ME
J Allergy Clin Immunol; 2010 Jun; 125(6):1336-43. PubMed ID: 20513524
[TBL] [Abstract][Full Text] [Related]
13. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
Oldhoff JM; Darsow U; Werfel T; Katzer K; Wulf A; Laifaoui J; Hijnen DJ; Plötz S; Knol EF; Kapp A; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
Allergy; 2005 May; 60(5):693-6. PubMed ID: 15813818
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Hart TK; Blackburn MN; Brigham-Burke M; Dede K; Al-Mahdi N; Zia-Amirhosseini P; Cook RM
Clin Exp Immunol; 2002 Oct; 130(1):93-100. PubMed ID: 12296858
[TBL] [Abstract][Full Text] [Related]
16. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
17. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity.
Egan RW; Athwal D; Bodmer MW; Carter JM; Chapman RW; Chou CC; Cox MA; Emtage JS; Fernandez X; Genatt N; Indelicato SR; Jenh CH; Kreutner W; Kung TT; Mauser PJ; Minnicozzi M; Murgolo NJ; Narula SK; Petro ME; Schilling A; Sehring S; Stelts D; Stephens S; Taremi SS; Zurcher J
Arzneimittelforschung; 1999 Sep; 49(9):779-90. PubMed ID: 10514907
[TBL] [Abstract][Full Text] [Related]
18. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.
Tomkinson A; Tepper J; Morton M; Bowden A; Stevens L; Harris P; Lindell D; Fitch N; Gundel R; Getz EB
Allergy; 2010 Jan; 65(1):69-77. PubMed ID: 19796211
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys.
Kasaian MT; Tan XY; Jin M; Fitz L; Marquette K; Wood N; Cook TA; Lee J; Widom A; Agostinelli R; Bree A; Schlerman FJ; Olland S; Wadanoli M; Sypek J; Gill D; Goldman SJ; Tchistiakova L
J Pharmacol Exp Ther; 2008 Jun; 325(3):882-92. PubMed ID: 18337474
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
